Blog Big Molecule Watch February 19, 2019

Pfizer Receives European Approval For Avastin® (Bevacizumab) Biosimilar

Pfizer announced today that the European Commission has approved its Avastin® (bevacizumab) biosimilar ZIRABEV for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix. ZIRABEV is Pfizer’s fifth biosimilar approved for use in Europe and has also been filed for regulatory approval with the FDA.

The post Pfizer Receives European Approval For Avastin® (Bevacizumab) Biosimilar appeared first on Big Molecule Watch.